StreetAlpha.app
Home › Stocks › SRRK

Scholar Rock Holding Corp (SRRK)

Healthcare
$48.13
▼ −4.45%
LAST CLOSE · NOV 20

Scholar Rock develops antibody medicines that target myostatin for spinal muscular atrophy and other rare neuromuscular diseases. It last closed at $48.13 on Nov 20, down 4.45% on the day. The next earnings report for SRRK is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, SRRK reported EPS of -$0.81 on revenue of $570,000. Over its last 8 reports the stock moved an average of 7.1% the session after earnings. Over the last 12 months SRRK insiders bought $12.0M of stock on the open market and sold $19.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is SRRK in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SRRK.

Key Stats

Last 12 months
Results
Revenue
$570K
Net income
−$413.6M
−72563.2% margin
EPS (diluted)
−$3.23
Free cash flow
−$309.9M
−54370.7% margin
Valuation
Market cap
$5.9B
122.0M shares
P/E
–
No P/E while losing money
Price to sales
10301.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$366.3M
At Sep 30
Debt
$196.2M
At Sep 30
Shareholder equity
$168.7M
Shares outstanding
122.0M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $18.8M$18.8MFY2021FY2022: $33.2M$33.2MFY2022FY2025: $0$0FY2025

From SRRK's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$0.81
Quarter ended Sep 2026
Year ago EPS
-$0.90
Same quarter last year
Revenue
$570,000
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.61Dec '24Mar 2025: -$0.67Mar '25Jun 2025: -$0.98Jun '25Sep 2025: -$0.90Sep '25Dec 2025: -$0.75Dec '25Mar 2026: -$0.83Mar '26Jun 2026: -$0.84Jun '26Sep 2026: -$0.81Sep '26Latest -$0.81
Revenue by quarter
Sep 2025: $0Sep '25Dec 2025: $0Dec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $570,000Sep '26Latest $570,000
How SRRK moved after its last 8 reports
Average move the session after a report ±7.1%
Nov 10, 2026Time not announced−6.9%
Aug 6, 2026Time not announced+10.0%
May 7, 2026Time not announced−1.4%
Mar 3, 2026Time not announced+1.9%
Jan 12, 2026Time not announced+3.3%
Nov 14, 2025Time not announced+24.4%
Aug 6, 2025Time not announced−6.4%
May 14, 2025Time not announced−2.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on SRRKStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on SRRK
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on SRRK

Technical Analysis

SRRK · as of the Nov 20 close · updated each morning
Turning up

The stock is 6% above its 20 day and 6% above its 50 day average. It is sitting right on its 200 day average, a level many traders watch. Momentum is strong (RSI 56). The nearest support is the swing low (Jul 22) at $47.27, and the nearest resistance the 200 day average at $48.27.

Short trendBullish
Long trendNeutral
MomentumStrong
StretchNormal
VolatilityHigh, 5.6%/day
Key levels
$61.7652 week high+28.3%
$51.73Swing high (Sep 23)+7.5%
$50.89Pivot R1+5.7%
$49.42100 day average+2.7%
$49.41Pivot+2.7%
$48.27200 day average+0.3%
$48.13Last close
$47.27Swing low (Jul 22)−1.8%
$46.66Pivot S1−3.1%
$45.4820 day average−5.5%
$45.2850 day average−5.9%
$37.5452 week low−22.0%
Indicators
RSI (14)55.78Middle of its rangeNeutral
MACD0.81Above its signal lineBullish
Stochastic64.0Middle of its rangeNeutral
ADX (14)28.3Trending up
Williams %R-43.4Oversold below −80, overbought above −20Neutral
CCI (20)126.5Oversold below −100, overbought above 100Overbought
Rate of change+2.5%Change over 10 sessionsBullish
ATR (14)$2.69Typical daily range, 5.6% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for SRRK

What happened before

See how SRRK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow SRRK usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How SRRK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for SRRKHow many large options trades hit SRRK, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

SRRK Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲186 buying vs 127 selling
  • ▲Held by funds +6.5 pts
  • ●Funds holding +3
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding311308+1.0%
In funds' top 10106+66.7%
Held by funds120.2%113.7%+6.5 pts
New / increased49 / 13755 / 129+1.1%
Reduced / sold out84 / 4382 / 21+23.3%
Put/call ratio1.722.22−22.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SRRK institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

SRRK Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$12.0M1 buy · 1 insider
Sold$19.4M26 sales · 13 insiders
45% of the selling was under pre-arranged trading plans.
2025-12 sold $6.2M2026-01 sold $7.3M2026-02 sold $1.8M2026-04 sold $3.1M2026-07 sold $923K2026-10 bought $12.0MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 26Srinivas AkkarajuDirectorBuy289,470$41.45$12.0M
Jul 1Katie PengDirectorSale plan5,446$53.88$293K
Jul 1Joshua ReedDirectorSale plan3,053$53.74$164K
Jul 1Kristina BurowDirectorSale plan3,053$53.74$164K
Jul 1Michael GilmanDirectorSale plan2,544$53.88$137K
Jul 1Jeffrey S. FlierDirectorSale plan3,053$53.88$164K
Every insider buy and sale for SRRK over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See SRRK insider trades →

From SEC Form 4 filings by SRRK's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SRRK is in one of them and how their past SRRK trades turned out.

SRRK in the AI portfolios
Loading…

SRRK News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SRRK in an article yet. Here's the latest on the wider market.

SRRK in the news

About Scholar Rock Holding

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts. It develops antibody medicines for people with spinal muscular atrophy (SMA) and other rare, severe neuromuscular diseases. Its lead product candidate, apitegromab, blocks myostatin, a protein that limits muscle growth, and is being studied in SMA and facioscapulohumeral muscular dystrophy. The company is also developing a subcutaneous form of apitegromab and is seeking regulatory approval in the United States and Europe.

Headquarters
Cambridge, MA